Nathan R. Foster
Papers
2
Total Citations
72
H-Index
2
About
Nathan R. Foster is a leading clinical researcher in the de-escalation of treatment for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. His work focuses on reducing the long-term toxic effects of aggressive cancer therapies while preserving high cure rates and quality of life for patients. Foster’s major contributions include the landmark MC1675 (DART) trial, a Phase III evaluation demonstrating that de-escalated adjuvant radiation therapy can be as effective as standard treatment, with 53 citations. He also led the MC1273 Phase II study, which showed that reduced adjuvant chemoradiation after transoral robotic surgery significantly lowers long-term toxic effects, improves swallow function, and enhances quality of life—garnering 19 citations. Together, these studies have reshaped clinical practice by providing evidence that less intensive therapy can maintain excellent oncologic outcomes while sparing patients from debilitating side effects. Foster’s work is highly impactful, with his most-cited papers accumulating over 70 citations, and his research is pivotal in advancing personalized, de-escalated treatment strategies for HPV-positive oropharyngeal cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2